Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Access Protocol for Advanced Cancer
NCT01419717Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2011
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of denosumab in bone metastasis, sponsored by Amgen. Started Nov 2011; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT01419717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01419717.